Acute Myocardial Infarction (AMI)DISCHARGE-MINCT06744322
Fast Discharge After Acute Myocardial Infarction Discharge MI
A study testing Fast discharge strategy in people with Acute Myocardial Infarction (AMI), run by Medical University Innsbruck at 8 sites in 2 countries.
Trial summary
To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction (AMI)
- What is being tested?
- Fast discharge strategy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,070 participants
- Where
- 8 sitesin 2 countries
- Study dates
- 1 Dec 2024to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
- Age ≥ 18 years at time of consent
- Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
- Ability to understand and willingness to sign and date written informed consent
Who cannot join
- Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
- PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
- Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
- Ongoing hemodynamic instability (systolic blood pressure <90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
- Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema)
- Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
Show all 10Show fewer
- Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3
- Pregnancy
- Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge
- Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team
Trial locations and contacts
8 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
Ivan Lechner, MD, PhD contact
8 sites in 2 countries
Austria7 sites, 7 recruiting
- Recruiting
Academic Teaching Hospital Feldkirch
Feldkirch, Vorarlberg, 6800
Matthias Frick, matthias.frick@lkhf.at
- Recruiting
Medical University of Graz
Graz, Styria, 8010
Dirk von Lewinski, dirk.von-lewinski@medunigraz.at
- Recruiting
Medical University of Innsbruck
Innsbruck, Tyrol, 6020
Martin Reindl, MD, PhD, +43 512 504 25665, martin.reindl@tirol-kliniken.at
Sebastian J Reinstadler, MD, PhD, sebastian.reinstadler@tirol-kliniken.at
- Recruiting
Paracelsus Medical University Salzburg
Salzburg, State of Salzburg, 5020
Uta Hoppe, u.hoppe@salk.at
- Not yet recruiting
Cardinal Schwarzenberg Hospital Schwarzach
Schwarzach im Pongau, Schwarzach Im Pongau, 5620
discharge@i-med.ac.at
- Recruiting
University Teaching Hospital Wels-Grieskirchen
Wels, Upper Austria, 4600
Ronald Binder, Ronald.Binder@klinikum-wegr.at
- Recruiting
Hospital Wiener Neustadt
Wiener Neustadt, Lower Austria, 2700
Franz Xaver Roithinger, franzxaver.roithinger@wienerneustadt.lknoe.at
Germany1 site, 1 recruiting
- Not yet recruiting
Ludwig Maximilian University Munich
Munich, Bavaria, 81377
Steffen Massberg, steffen.massberg@med.uni-muenchen.de
About this study
Official title: Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial
To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.
Read the detailed description
The goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. The trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge >36 hours) with respect to the risk of major adverse cardiovascular events at 12 months.
- Conditions
- Acute Myocardial Infarction (AMI)
- Being tested
- Fast discharge strategy
- Keywords
- Myocardial Infarction, STEMI, NSTEMI, Discharge, Randomized
- Medical subject headings
- Myocardial Infarction, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fast discharge strategyProcedure or surgery
Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
| Study group | Role | What they receive |
|---|---|---|
| Standard Care | No intervention | Patients undergo a standard post-infarction care, with discharge at >36 hours after invasive management of acute myocardial infarction. |
| Fast discharge strategy | Experimental | Fast discharge at 24 (+/-12) hours after invasive management of acute myocardial infarction. Receives: Procedure: Fast discharge strategy |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACE
MACE is defined as a composite of all-cause death, myocardial re-infarction and unscheduled cardiovascular re-hospitalization.
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Secondary outcomes (12)
All cause death
Death from any cause.
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with myocardial re-infarction
Number of participants experiencing myocardial re-infarction
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with unscheduled cardiovascular re-hospitalization
Number of participants with unscheduled cardiovascular re-hospitalization
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with Cardiovascular death
Number of participants experiencing cardiovascular-related death
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants hospitalized for heart failure
Number of participants hospitalized for heart failure
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants expiring hospitalization from any cause
Number of participants expiring hospitalization from any cause
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of patients experiencing a stroke
Number of patients experiencing a stroke
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with a bleeding event
Number of participants with a bleeding event
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Healthcare costs per patient between randomization and 12 months
An economic evaluation will be conducted from the healthcare payer perspective. Direct healthcare costs, including intervention costs, hospitalizations, outpatient visits, diagnostic procedures, and concomitant medications, will be collected prospectively for each participant over the study period. Mean total healthcare costs per patient will be calculated and compared between study groups.
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Length of hospital stay
Number of days in hospital from time of infarction to hospital discharge
Measured: From the date of randomization to the date of hospital discharge, for up to 100 days
Percentage of patients on guideline-directed therapy
Percentage of patients on guideline-directed therapy
Measured: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Infection
Infection leading to hospitalization
Measured: At 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2024
- Study start1 Dec 2024
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- More trials run by Medical University InnsbruckThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 2,070 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University Innsbruck
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Martin Reindl, MD, PhD, Principal investigator, Medical University InnsbruckSebastian J Reinstadler, MD, PhD, Principal investigator, Medical University Innsbruck
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06744322
- Sponsor's protocol ID
- 1284/2024
- Other IDs
- 20241113-3609
- Acronym
- DISCHARGE-MI
- Status last verified
- Jan 2026
- First submitted
- 13 Dec 2024
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial
- ClinicalTrials.gov ID
- NCT06744322
- Acronym / sponsor ID
- DISCHARGE-MI / 1284/2024
- Conditions
- Acute Myocardial Infarction (AMI)
- Keywords
- Myocardial Infarction, STEMI, NSTEMI, Discharge, Randomized
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,070 participants (estimated)
- Lead sponsor
- Medical University InnsbruckUniversity, hospital or other
- Study start
- 1 Dec 2024 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 20 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.
Detailed description
The goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. The trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge >36 hours) with respect to the risk of major adverse cardiovascular events at 12 months.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard Care | No intervention | –Patients undergo a standard post-infarction care, with discharge at >36 hours after invasive management of acute myocardial infarction. |
| Fast discharge strategy | Experimental | Procedure: Fast discharge strategyFast discharge at 24 (+/-12) hours after invasive management of acute myocardial infarction. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
- Age ≥ 18 years at time of consent
- Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
- Ability to understand and willingness to sign and date written informed consent
Key exclusion criteria (10 listed)
- Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
- PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
- Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
- Ongoing hemodynamic instability (systolic blood pressure <90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
- Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fast discharge strategyPatients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours. | Procedure or surgery | Fast discharge strategy |
Primary outcome
MACE
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
MACE is defined as a composite of all-cause death, myocardial re-infarction and unscheduled cardiovascular re-hospitalization.
12 secondary outcomes
All cause death
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with myocardial re-infarction
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with unscheduled cardiovascular re-hospitalization
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with Cardiovascular death
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants hospitalized for heart failure
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants expiring hospitalization from any cause
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of patients experiencing a stroke
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with a bleeding event
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Healthcare costs per patient between randomization and 12 months
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Length of hospital stay
Time frame: From the date of randomization to the date of hospital discharge, for up to 100 days
Percentage of patients on guideline-directed therapy
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Infection
Time frame: At 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Myocardial Infarction (AMI)
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ivan Lechner, MD, PhD contact
Martin Reindl, MD, PhD principal investigator
Medical University Innsbruck
Sebastian J Reinstadler, MD, PhD principal investigator
Medical University Innsbruck
8 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fast discharge strategy in people with Acute Myocardial Infarction (AMI), run by Medical University Innsbruck at 8 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Austria, Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Martin Reindl, MD, PhD (+43 512 504 25665, martin.reindl@tirol-kliniken.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACE (time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.